tbuckley/cabot-search huggingface dataset:
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Osagie Ebekozien, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Jason L. Gaglia, Rajesh Garg, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Robert C. Stanton, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Mandeep Bajaj, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Jason L. Gaglia, Rajesh Garg, Monica Girotra, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Joshua J. Neumiller, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Rajesh Garg, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Introduction and Methodology: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Mandeep Bajaj, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Kenneth Cusi, Sandeep R. Das, Osagie Ebekozien, Justin B. Echouffo-Tcheugui, Barbara Eichorst, Laya Ekhlaspour, Talya K. Fleming, Robert G. Frykberg, Jason L. Gaglia, Rodolfo J. Galindo, Rajesh Garg, Sunir J. Garg, Monica Girotra, John M. Giurini, Mohamed Hassanein, Kamlesh Khunti, Mikhail N. Kosiborod, Robert F. Kushner, Rayhan Lal, Seymour R. Levin, Ildiko Lingvay, Glenn Matfin, Roeland J.W. Middelbeek, Lisa Murdock, Nicola Napoli, Joshua J. Neumiller, Naushira Pandya, Sharon J. Parish, Elizabeth J. Pekas, Scott J. Pilla, Flavia Q. Pirih, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Shylaja Srinivasan, Robert C. Stanton, Molly L. Tanenbaum, Patti Urbanski, Monica Verduzco-Gutierrez, Crystal C. Woodward, Zobair M. Younossi, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Sandeep R. Das, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Rajesh Garg, Kamlesh Khunti, Mikhail N. Kosiborod, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2025
Authors: Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Osagie Ebekozien, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Rajesh Garg, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Raveendhara R. Bannuru
Journal: Diabetes Care (2024)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced <i>KRAS</i> mutant non-small cell lung cancer
Authors: Mitchell S. von Itzstein, Timothy F. Burns, Jonathan E. Dowell, Leora Horn, D. Ross. Camidge, Sally J. York, Keith D. Eaton, Kelly Kyle, Farjana J. Fattah, Jialiang Liu, Hong Mu-Mosley, Arjun Gupta, Urooba Nadeem, Ang Gao, Song Zhang, David E. Gerber
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated advanced KRAS mutant NSCLC. Patients and Methods: The primary outcome of this multi-center phase 1/2 dose escalation trial of selinexor plus docetaxel was safety and tolerability. Selinexor was started one week before docetaxel to permit monotherapy pharmacodynamic assessment. Results: Among 40 enrolled patients, median age was 66 years, 55% were female, and 85% were white. Maximum tolerated dose was selinexor 60 mg orally weekly plus docetaxel 75 mg/m2 every three weeks. The most common adverse events were nausea (73%, 8% Gr ≥3), fatigue (70%, 5% Gr ≥3), neutropenia (65%, 60% Gr ≥3), and diarrhea (58%, 10% Gr ≥3). Of 32 efficacy evaluable patients, 7 (22%) had partial responses and 18 (56%) had stable disease. Outcomes were not associated with KRAS mutation type but were significantly better in cases with wild type TP53 (42%), including disease control and response rates (27% and 80%, vs. 9% and 27%, respectively; P=0.03) and progression-free survival (median 7.4 vs. 1.8 months; HR, 0.2; 95% CI, 0.07-0.67; P=0.003). Post-selinexor / pre-docetaxel, serum LDH levels increased an average 51 U/L in TP53 altered and decreased an average 48 U/L in TP53 wild type cases (P=0.06). Conclusions: Selinexor plus docetaxel was relatively well tolerated in patients with advanced KRAS mutant NSCLC. The regimen has promising efficacy in TP53 wild type cases, where selinexor monotherapy may also have activity.
Corrigendum to “Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade” [Journal of Controlled Release 332 (2021) 194–209]
Authors: Xiaowei Liu, Yanlin Feng, Jie Xu, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang, Hubing Shi
Journal: Journal of Controlled Release (2024)
10‐Year Risk of Gallstones in Congenital Red Blood Cell Disorder Patients: A Nationwide Cohort Study
Authors: Anders Blach Naamansen, Dennis Lund Hansen, Jesper Petersen, Andreas Glenthøj, Henrik Toft Sørensen, Henrik Frederiksen
Journal: American Journal of Hematology (2024)

ABSTRACT Chronic hemolysis potentially elevates the risk of gallstones in several types of congenital red blood cell (RBC) disorders. However, the magnitude of the risk is unknown. We investigate the risk of gallstone disease in congenital RBC disorder patients, compared with general population comparators. Patients were identified from the Danish National Patient Registry covering all Danish hospitals and the National Reference Laboratory for RBC disorders during 1980–2016. Patients were matched by sex, age, and region of origin with up to 50 general population comparators. Gallstone events were identified using hospital‐registered diagnoses and surgery codes. Our study included 9354 congenital RBC disorder patients, grouped according to type of congenital RBC disorder, and 416 994 general population comparators. The cumulative 10‐year incidence of gallstone disease was 4.2% in patients with congenital RBC disorders and 1.7% among comparators. Adjusted csHR's [95% confidence interval] were 8.1 [6.8, 9.7] for hereditary spherocytosis; 3.3 [1.6, 6.8] for glucose‐6‐phosphate dehydrogenase deficiency; 21.6 [10.6, 44.1] for pyruvate kinase deficiency; 3.7 [1.9, 7.0] for sickle cell disease; 0.8 [0.4, 1.6] for sickle cell trait; 1.5 [1.1, 2.2] for α‐thalassemia trait; 1.8 [1.4, 2.3] for β‐thalassemia minor; and 2.1 [1.8, 2.6] for other congenital hemolysis. We found a markedly higher risk of hospital‐registered gallstone diseases in nearly all groups of patients with congenital RBC disorders compared with the general population.
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation
Authors: Viral Shah, George Giotopoulos, Hikari Osaki, Markus Meyerhöfer, Eshwar Meduri, Aaron Gallego-Crespo, Malte Andreas Behrendt, Maria Saura-Pañella, Aarti Tarkar, Benedict Schubert, Haiyang Yun, Sarah J. Horton, Shuchi Agrawal-Singh, Patricia S Hähnel, Faisal Basheer, Dave Lugo, Ioanna Eleftheriadou, Olena Barbash, Arindam Dhar, Michael Kühn, Borhane Guezguez, Matthias Theobald, Thomas Kindler, Paolo Gallipoli, Paul Sung-Hao Yeh, Mark A. Dawson, Rab K Prinjha, Brian JP Huntly, Daniel Sasca
Journal: Blood (2024)
Throw out an oligopeptide to catch a protein: Deep learning and natural language processing-screened tripeptide PSP promotes Osteolectin-mediated vascularized bone regeneration
Authors: Yu Chen, Long Chen, Jinyang Wu, Xiaofeng Xu, Chengshuai Yang, Yong Zhang, Xinrong Chen, Kaili Lin, Shilei Zhang
Journal: Bioactive Materials (2024)
A ceramic microbridge microfluidic chip to study osteogenic differentiation of mesenchymal stem cells in bioactive ceramic immune microenvironment
Authors: Sheng Ye, Quanle Cao, Panxianzhi Ni, Shuting Xiong, Meng Zhong, Tun Yuan, Jing Shan, Jie Liang, Yujiang Fan, Xingdong Zhang
Journal: Bioactive Materials (2024)
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
Authors: Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, Francesco Malvestiti, Ruifang Li-Gao, Rosellina M. Mancina, Marcus Alvarez, Kyla Gelev, Samantha Maurotti, Umberto Vespasiani-Gentilucci, Frits Richard Rosendaal, Julia Kozlitina, Päivi Pajukanta, François Pattou, Luca Valenti, Stefano Romeo
Journal: Nature Medicine (2024)

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by an excess of lipids, mainly triglycerides, in the liver and components of the metabolic syndrome, which can lead to cirrhosis and liver cancer. While there is solid epidemiological evidence that MASLD clusters with cardiometabolic disease, several leading genetic risk factors for MASLD do not increase the risk of cardiovascular disease, suggesting no causal relationship between MASLD and cardiometabolic derangement. In this work, we leveraged measurements of visceral adiposity identifying 27 previously unknown genetic loci associated with MASLD ( n = 36,394), six replicated in four independent cohorts ( n = 3,903). Next, we generated two partitioned polygenic risk scores based on the presence of lipoprotein retention in the liver. The two polygenic risk scores suggest the presence of at least two distinct types of MASLD, one confined to the liver resulting in a more aggressive liver disease and one that is systemic and results in a higher risk of cardiometabolic disease. These findings shed light on the heterogeneity of MASLD and have the potential to improve the prediction of clinical trajectories and inform precision medicine approaches.
Neutrophils in cancer: from biology to therapy
Authors: Leo Koenderman, Nienke Vrisekoop
Journal: Cellular and Molecular Immunology (2024)

Abstract The view of neutrophils has shifted from simple phagocytic cells, whose main function is to kill pathogens, to very complex cells that are also involved in immune regulation and tissue repair. These cells are essential for maintaining and regaining tissue homeostasis. Neutrophils can be viewed as double-edged swords in a range of situations. The potent killing machinery necessary for immune responses to pathogens can easily lead to collateral damage to host tissues when inappropriately controlled. Furthermore, some subtypes of neutrophils are potent pathogen killers, whereas others are immunosuppressive or can aid in tissue healing. Finally, in tumor immunology, many examples of both protumorigenic and antitumorigenic properties of neutrophils have been described. This has important consequences for cancer therapy, as targeting neutrophils can lead to either suppressed or stimulated antitumor responses. This review will discuss the current knowledge regarding the pro- and antitumorigenic roles of neutrophils, leading to the concept of a confused state of neutrophil-driven pro-/antitumor responses.
Dissociable control of motivation and reinforcement by distinct ventral striatal dopamine receptors
Authors: Juan Enriquez-Traba, Miguel Arenivar, Hector E. Yarur-Castillo, Chloe Noh, Rodolfo J. Flores, Tenley Weil, Snehashis Roy, Ted B. Usdin, Christina T. LaGamma, Huikun Wang, Valerie S. Tsai, Damien Kerspern, Amy E. Moritz, David R. Sibley, Andrew Lutas, Rosario Moratalla, Zachary Freyberg, Hugo A. Tejeda
Journal: Nature Neuroscience (2024)
Thermally induced neuronal plasticity in the hypothalamus mediates heat tolerance
Authors: Wojciech Ambroziak, Sara Nencini, Jörg Pohle, Kristina Zuza, Gabriela Pino, Sofia Lundh, Carolina Araujo-Sousa, Larissa I. L. Goetz, Katrin Schrenk-Siemens, Gokul Manoj, Mildred A. Herrera, Claudio Acuna, Jan Siemens
Journal: Nature Neuroscience (2024)

Abstract Heat acclimation is an adaptive process that improves physiological performance and supports survival in the face of increasing environmental temperatures, but the underlying mechanisms are not well understood. Here we identified a discrete group of neurons in the mouse hypothalamic preoptic area (POA) that rheostatically increase their activity over the course of heat acclimation, a property required for mice to become heat tolerant. In non-acclimated mice, peripheral thermoafferent pathways via the parabrachial nucleus activate POA neurons and mediate acute heat-defense mechanisms. However, long-term heat exposure promotes the POA neurons to gain intrinsically warm-sensitive activity, independent of thermoafferent parabrachial input. This newly gained cell-autonomous warm sensitivity is required to recruit peripheral heat tolerance mechanisms in acclimated animals. This pacemaker-like, warm-sensitive activity is driven by a combination of increased sodium leak current and enhanced utilization of the Na V 1.3 ion channel. We propose that this salient neuronal plasticity mechanism adaptively drives acclimation to promote heat tolerance.
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
Authors: Violeta Raverdy, Federica Tavaglione, Estelle Chatelain, Guillaume Lassailly, Antonio De Vincentis, Umberto Vespasiani-Gentilucci, Sami F. Qadri, Robert Caiazzo, Helene Verkindt, Chiara Saponaro, Julie Kerr-Conte, Gregory Baud, Camille Marciniak, Mikael Chetboun, Naima Oukhouya-Daoud, Samuel Blanck, Jimmy Vandel, Lisa Olsson, Rima Chakaroun, Viviane Gnemmi, Emmanuelle Leteurtre, Philippe Lefebvre, Joel T. Haas, Hannele Yki-Järvinen, Sven Francque, Bart Staels, Carel W. Le Roux, Valentina Tremaroli, Philippe Mathurin, Guillemette Marot, Stefano Romeo, François Pattou
Journal: Nature Medicine (2024)

Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits considerable variability in clinical outcomes. Identifying specific phenotypic profiles within MASLD is essential for developing targeted therapeutic strategies. Here we investigated the heterogeneity of MASLD using partitioning around medoids clustering based on six simple clinical variables in a cohort of 1,389 individuals living with obesity. The identified clusters were applied across three independent MASLD cohorts with liver biopsy (totaling 1,099 participants), and in the UK Biobank to assess the incidence of chronic liver disease, cardiovascular disease and type 2 diabetes. Results unveiled two distinct types of MASLD associated with steatohepatitis on histology and liver imaging. The first cluster, liver-specific, was genetically linked and showed rapid progression of chronic liver disease but limited risk of cardiovascular disease. The second cluster, cardiometabolic, was primarily associated with dysglycemia and high levels of triglycerides, leading to a similar incidence of chronic liver disease but a higher risk of cardiovascular disease and type 2 diabetes. Analyses of samples from 831 individuals with available liver transcriptomics and 1,322 with available plasma metabolomics highlighted that these two types of MASLD exhibited distinct liver transcriptomic profiles and plasma metabolomic signatures, respectively. In conclusion, these data provide preliminary evidence of the existence of two distinct types of clinically relevant MASLD with similar liver phenotypes at baseline, but each with specific underlying biological profiles and different clinical trajectories, suggesting the need for tailored therapeutic strategies. Partitioning clustering based on clinical variables applied to multiple patient cohorts identifies two subtypes of metabolic dysfunction-associated steatotic liver disease with different associations to hepatic and cardiovascular outcomes.
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Authors: Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J. Higgins, Roisin M. Connolly, Sally Baron-Hay, María Gión, Valentina Guarneri, Giampaolo Bianchini, Hans Wildiers, Santiago Escrivá-de-Romaní, Manoj Prahladan, Helen Bridge, Nataliya Kuptsova-Clarkson, Nana Scotto, Sunil Verma, Nancy U. Lin, Belinda Yeo, Nicole McCarthy, Amelia McCartney, Timothy Clay, Nicholas Murray, Andrea Gombos, Joëlle Collignon, Eveline De Cuypere, Katarzyna Jerzak, Stephen Chia, Maja Maraldo, Jeanette Rønlev, Eva Brix, Minna Tanner, Johanna Mattson, Riikka Huovinen, Pauline Wimberger, Mattea Reinisch, Hans Tesch, Michael Untch, Peter Fasching, Tjoung-Won Park-Simon, Joke Tio, Michael Braun, Eva Maria Grischke, Frederik Marmé, Marion van Mackelenbergh, John McCaffrey, Michelino De Laurentiis, Michele Caruso, Rossana Berardi, Laura Biganzoli, Vittoria Fotia, Toshinari Yamashita, Junji Tsurutani, Koichiro Tsugawa, Nobumoto Tomioka, Maaike de Boer, Daniel Houtsma, Martin Pilskog, Olav Engebråten, Anna Sætersdal, Piotr Wysocki, Zbigniew Nowecki, Barbara Radecka, Jacek Jassem, Renata Duchnowska, Joana Simões, Fatima Cardoso, Ana Rita Sousa, María Jesús Vidal Losada, Cristina Saura Manich, Joaquin Gavilá Gregori, Maria Pilar Lopez Marti, Manuel Ruiz Borrego, Javier Cortés Castán, Rafael López López, César Rodríguez Sanchez, Encarnación González Flores, Carmen Hinojo González, Purificación Martínez del Prado, Aglaia Schiza, Fredrika Killander, Leif Klint, Lorenzo Rossi, Stefan Aebi, Khalil Zaman, Peter Hall, Carey Anders
Journal: Nature Medicine (2024)
Association of idealized amphiphiles and protease inhibitors: conferring antimicrobial peptides with stable antibacterial activity under physiological conditions to combat multidrug-resistant bacteria
Authors: Yongjie Zhu, Bowen Li, Wanying Xu, Yuanmengxue Wang, Guoyu Li, Chongpeng Bi, Changxuan Shao, Anshan Shan
Journal: Drug Resistance Updates (2024)
The presence of Clostridioides difficile in faeces before and after faecal microbiota transplantation and its relation with recurrent C. difficile infection and the gut microbiota in a Dutch cohort
Authors: Bas Groenewegen, Emilie van Lingen, Artemiy Kovynev, Alexander J van den Berg, Eric K L Berssenbrugge, Ingrid M J G Sanders, Joffrey van Prehn, Els van Nood, Abraham Goorhuis, Ed J Kuijper, Wiep Klaas Smits, Maria Wiese, Josbert J Keller, Quinten R Ducarmon, Elisabeth M Terveer
Journal: Clinical Microbiology and Infection (2024)